The content on this site is intended for healthcare professionals only
Dr Rimawi speaks with ecancertv at SABCS 2016 about the results of a trial in which neoadjuvant TCHP chemotherapy was administered alongside oestrogen deprivation therapy in HR/HER positive breast cancer patients.
He considers comments that the chemotherapy regimen seems to blunt the clinical benefit of anti-oestrogens, which may in turn be attributable to the sheer success of chemotherapy, or be influenced by the timing and dosage of the regimens.
These results were first presented in a press conference session, with video available here.
Best practice in precision medicine for prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
OncoAlert Round Up for August 25th - 31st, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Latest in PARP inhibitors and combination therapies for prostate cancer
Loco-regional management after neoadjuvant chemotherapy
